Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 464 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Arm 1- Dose Expansion Clear all

Conditions: Lymphoma, Non-Hodgkin Lymphoma, NHL, Hematologic Malignancies, Lymphoid Malignancies
Interventions: Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152, Prednisone, PET, EKG, ECHO, CT neck chest, abdomen, and pelvis, MRI, Bone marrow aspiration/Biopsy; Device · Drug · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: B Cell Precursor Acute Lymphoblastic Leukemia
Interventions: Blinatumomab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 13
States / cities: Clovis, California • Duarte, California • Chicago, Illinois + 10 more

Conditions: Glioma
Interventions: rhIL-7-hyFc, Placebo, Temozolomide, Radiation therapy; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
Interventions: CNTY-101, IL-2, Lymphodepleting Chemotherapy; Biological · Drug
Lead sponsor: Century Therapeutics, Inc.; Industry
Eligibility: 17 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Sacramento, California • Chicago, Illinois + 3 more

Conditions: Ovarian Neoplasms, Endometrial Neoplasms, Breast Neoplasms
Interventions: PF-07260437, B7-H4 IHC; Drug · Diagnostic Test
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: Duarte, California • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: Breast Cancer
Interventions: Ipatasertib, Paclitaxel, Atezolizumab, Nab-Paclitaxel, AC; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
Interventions: STK-012, pembrolizumab KEYTRUDA®, pemetrexed, carboplatin; Drug
Lead sponsor: Synthekine; Industry
Eligibility: 18 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 35
States / cities: Tucson, Arizona • Beverly Hills, California • Fullerton, California + 28 more

Conditions: Leukemia, Myeloid, Acute
Interventions: DCLL9718S, Azacitidine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: Duarte, California • Aurora, Colorado • New Haven, Connecticut + 2 more

Conditions: Brain Metastases, Lung Cancer, Breast Cancer, Melanoma, Malignant Glioma
Interventions: 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks, 2B3-101 50 mg/m2 every 3 weeks; Drug
Lead sponsor: BBB-Therapeutics B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer
Interventions: SON-DP; Drug
Lead sponsor: Qurgen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Gilbert, Arizona • Detroit, Michigan • Huntersville, North Carolina + 2 more

Conditions: Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, Pancreatic Cancer, Bile Duct Cancer, Endometrial Cancer, Melanoma Cancer, Urothelial Cancer
Interventions: PF-06940434, PF-06801591; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 18
States / cities: Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 9 more

Conditions: Acute Myelogenous Leukemia
Interventions: Azacitidine, Venetoclax, Pevonedistat; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Rochester, Minnesota • Milwaukee, Wisconsin

Conditions: Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Receiving CAR-T Therapy
Interventions: Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T; Other · Drug
Lead sponsor: AvenCell Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Chicago, Illinois • Evanston, Illinois • Providence, Rhode Island + 2 more

Conditions: Metastatic Castrate Resistant Prostate Cancer
Interventions: Docetaxel, Radium 223; Drug · Radiation
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 4
States / cities: Boston, Massachusetts • Detroit, Michigan • Columbus, Ohio

Conditions: Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
Interventions: Obinutuzumab, Prednisone, Revlimid, Polatuzumab, Ibrutinib, Venetoclax, EKG, Bone marrow aspiration, Bone marrow biopsy, CT, MRI, PET, Tumor tissue/Biopsy, Acetaminophen, Diphenhydramine, Polatuzumab; Biological · Drug · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neoplasms
Interventions: MK-4830, Pembrolizumab, Carboplatin, Pemetrexed, Lenvatinib, Paclitaxel, Cisplatin, MK-4830A; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 9
States / cities: San Francisco, California • Detroit, Michigan • St Louis, Missouri + 6 more

Conditions: Advanced or Metastatic Solid Tumors
Interventions: BH3120, pembrolizumab; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 5
States / cities: Tampa, Florida • Grand Rapids, Michigan • Cincinnati, Ohio + 2 more

Conditions: Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC), Bladder Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Advanced or Metastatic
Interventions: CP-383; Drug
Lead sponsor: Tasca Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 13
States / cities: Denver, Colorado • Orlando, Florida • Grand Rapids, Michigan + 10 more

Conditions: Breast Neoplasms
Interventions: LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane, Everolimus, Trastuzumab, LY3023414, Fulvestrant, Pertuzumab, Loperamide, Endocrine therapy; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 13
States / cities: Rogers, Arkansas • La Jolla, California • Boston, Massachusetts + 7 more

Conditions: Metastatic or Locally-advanced Unresectable Breast Cancer
Interventions: BYL719, Letrozole, Exemestane; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Glioma, Glioblastoma, Brain Neoplasms
Interventions: YN003 Injection; Drug
Lead sponsor: Beijing Inno Medicine Co., Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Los Angeles, California • San Francisco, California • Houston, Texas

Conditions: Neoplasms
Interventions: OMO-1; Drug
Lead sponsor: Octimet Oncology N.V.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Advanced Solid Tumors
Interventions: axitinib, crizotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 15
States / cities: Chicago, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 5 more

Conditions: KRAS p.G12C Mutant Advanced Solid Tumors
Interventions: sotorasib, Anti PD-1/L1, Midazolam; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 39
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 29 more

Search by objective public record fields.

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

A Study of PF-07260437 in Advanced or Metastatic Solid Tumors

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer

A Phase I Clinical Study of YN003 in the Treatment of Glioma

OMO-1 in Solid Malignancies

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)